[b]I hate to advocate drugs, alcohol, violence, or insanity to anyone, but they've always worked for me.[/b]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ARbigguy1 it is indeed amazing how the AI remains the same yet the formulation to tweek it in some way changes, and valuation of these new formulations continues.
Pete, mick, totally agree with that. Cannot beat these prices.
Noticed that accumulation/distribution is almost going straight up.
Accumulators are excited, that's for sure.
Still waiting for my other, would like nothing more than to buy at these levels. When I'm ready to jump in that is when she moves. Such is my so called life...…. Phase 2b coming.
Elite has much experience with Ritalin. From what I understood Mehta brokered the Ritalin technology into ~$700 million. Seemed like a lot of money back then, but remember this, they had no steady revenue stream to help support the company like the generics they have today Makes too much sense for it not to Ritalin. Back then Elite had come up with a pulse technology. SunGen's platform is a gamechanger not just for Ritalin, but for all generic drugs across the board.
NH one smart cookie.
Of course if one knew anything about Elite they would have realized this
when NASDAQ brought it up. Question is, what technological advantage does SunGen have in their PIP that may be a game changer? And there is a very good chance that Elite/SunGen could take market share if this $1.6 billion space for this ONE CNS drug. SunGen's platform is game changing...….
Feel free to answer one and all...… should be good for a few laughs!
From 2000
Elite's Atul M. Mehta was recently issued a U.S. patent (No. 5,837,284) related to pulse dose methylphenidate products. The patent was exclusively licensed to Celgene Corp. (Warren, NJ), who then licensed the product to Novartis (see related article). Elite retains certain manufacturing rights for the patented product—which simulates two doses of the drug marketed as Ritalin—and also retained rights to its pulse dose technology as it relates to all non-methylphenidate drugs.
Hmmmmmmm interesting stuff alright! gggggg
This Avatar formulation will use SunGen's proprietary platform, as well as any of the formulations Elite/SunGen collaborate on.
So, what will differentiate this formulation from what is currently on the market? Stay tuned.
Say it ain't so~! LOL
Nonsense. Post the proof. Thanks in advance.
Absolutely false, inaccurate, and misleading. No investigations are going on at Elite.
If so.....just post the proof.
Support which was dismal at $0.08 is now pretty strong at $0.09.
All in a matter of a day. Could not push it below $0.08 despite
no news. $0.05 isn't coming anytime soon, but try to push it down for giggles.
LOL
Not true..... those who have been in the stock know that PMCB attracts
savvy investors with an eye toward the future of medical delivery technology. But will give a gold star for trying...…….
NASDAQ I keep mentioning SunGen's proprietary technology but folks just aren't listening. Guess we will have to let this formulation speak for itself when the time comes.
Actually Conix you're wrong on that. The fact that Elite has 5 ANDAs submitted plus 1 NDA submitted is very positive.
Elite's technologies will be a significant pipeline for any companies interested in adding it to their current pipeline. The Elite/SunGen formulations will be using SunGen's PIP, so those that say these formulations will not make a dent in current markets could be wrong.
Proof of concept is all that Elite needs right now. That proof of concept will come with approvals. So, we wait for the FDA.
Could very well be YJ4LIFE.
1000 x $8.50 = $85.00 even better.......
Hey ya just never know in this fickle market. Stranger things have happened.
100 X 0.085 = $8.50, still well short of $8.75 target set by the Redeye guy. But I'll take it.
Purdue's flunkies couldn't solve their own ADF issues and had the chance to grab Elite's ADF technology for next to nothing and failed to do so.
Why?
Because Purdue thought they had the situation in hand, when all along it was Elite that had the right polymer... not Purdue.... Oppppsy!
Then Purdue developed OxyContin..... the abuse resistant hard turtle shell
formulation that can easily be abused. Elite has a solution for that as well.... Elite's own version which already has been submitted to the FDA.
Nice try Purdue. Strike two...... next strike you are OUT!
But let's not forget that Purdue is tapping into markets outside of the US under another pharmaceutical name. Same company different name exploiting
people and markets outside of the US with their non ADF garbage.
When it comes to making money anyway they can without regard for safety
we can always count on that company to do what it can for themselves.
Just one approval will more than likely do it.
A few approvals will be awesome as revenues ramp UP.
Gottlieb was supposed to be the answer to get ANDAs approved faster. I see no evidence of that and think that was all smoke and mirrors. Same old FDA.
Troxyca approved yet can be abused with common chemicals. Why didn't the FDA see this? Now years after approval by the FDA this sort of breach in the formulation is found? Total bullshit and again because it was Pfizer, a trusted name in pharmaceuticals, Pfizer was granted approval. Why didn't the FDA do their diligence with Pfizer as they do with other companies?
Money screams volumes.........
LOL toofun. Good post that sums it up well.
Hopefully Elite doesn't have to do another fed BE study for SequestOx, but chances are pretty good they may have to.
And the timelines for all ANDAs submitted are guestimates. So far this FDA
under Gottlieb is no different than the FDA under Califf.
So Elite has had to do a cut tablet stability on Percocet. Norco was also mentioned, but Elite has decided to pass on Norco for now while addressing
the current ANDA Elite/SunGen will be submitting.
That will make 6 ANDAs and one NDA.
Yes, let's get this straight once and for all, sloppy Pfizer can't get a reliable ADF out on the market after spending 10s or hundreds of millions
on their formulations.... yet little itty bitty Elite can and will.
I agree... pretty unbelievable.
Me at whatever NH decides to sell the company for.
Nice find NAS. Pfizer knew of this problem before even putting out to market more than likely. Saved the company a whole lot of grief and money.
Now that we know why Troxica was discontinued after Pfizer spent millions on this formulation, doesn't it stand to reason that other opioids from Pfizer using the same formulation may also carry the same potential for abuse, such as Embeda?
Guess Pfizer's HAL testing for Troxica fell short, and it isn't like the company doesn't have the money. Just sloppy on Pfizer's part. Real sloppy and arrogant. But that's big pharma for ya. Looks as if Elite will not get their comparator from sloppy Pfizer.
Bollinger bands are opening and volatility is to the downside for now.
Support is 16 at $0.09. This drops to 2 at $0.09 and $0.08.
For close to a month now stock price has been sideways and volume low.
1 NDA and 5 ANDAs........
The SEC
No proof that there isn't naked shorting in Elite either. Otherwise that burden of proof is on you.
The naked short sword has two edges..... cuts both ways doc.
Hmmmm, wonder if this has anything to do with any Pfizer ADFs? LOL~!
This will make... what? 2 or 3 years approval was granted and still nothing on the shelves? What is Pfizer worried about? A little company like Elite using their formulation as a comparator?
LOL~!
The whole ball of wax here centers around naked shorting. The SEC recognizing that this is a prevailing problem is 50% of the battle.
They will figure it out..... just like everything else.... if more regulation is needed, trust me they will figure it out. The SEC knows this has been a problem for a long time and also knows the fraud that occurs tied to naked shorting. Honest investors are getting hammered along with some very reputable companies. It has to be addressed. Too much money in play here.
In the pharmaceutical biotech biz when a CEO says it will not take that much time, is he talking about days weeks months or years?
Now remember, this is the FDA, and this is the pharmaceutical/biotech sector.
What may not take that much time in KW's mind may be a long time to the layman who has no inkling about this sector or the FDA.
Getting nervous? LOLOLOL~!
OTCbb stocks are where most problem companies reside. As was seen with Elite for example, 3 years ago Elite was manipulated to a share price of
$0.97 on NO NEWS. Folks who manipulated the share price to this point made money going up as well as going back down.
The OTCbb is most vulnerable to this type of action. The hammer will come down on all exchanges, however, I believe the SEC will concentrate on OTCbb exchange as well. Companies are trying to get off the OTCbb exchange due to extreme manipulation of share prices with naked shorting. Higher exchanges are much less likely to have this type of manipulation. Investment firms plunk their money into the higher exchanges too. The OTCbb is highly unregulated with regard to naked shorting and other manipulation practices. SEC knows this, maybe they will finally do something about it.